Skip to main content
TipRanks
Go Ultimate75% OFF

AOTI, Inc. (AOTI) AI Stock Analysis

3 Followers
GB:AOTI

AOTI, Inc.

(LSE:AOTI)

Select Model
Rating:70Outperform
Price Target:GBX 160.00▲(10.34% Upside)
Action:upgraded
Date:10/01/26

AOTI's overall score is primarily driven by strong technical momentum and a highly optimistic earnings call, highlighted by a proposed CMS coverage milestone that could exponentially expand its addressable market. The stock is in a robust uptrend across all major moving averages. However, the score is tempered by a high valuation premium and mixed financial fundamentals; despite achieving GAAP profitability, historical structural cash burn, rising leverage, and uncollected Arizona Medicaid receivables present notable risks.

Positive Factors
Revenue growth and profitabilityThe sharp 2025 revenue acceleration and transition to positive operating profit and net income indicate improving commercial scale. If growth continues, greater volume can support operating leverage, strengthen the platform’s market position, and provide more resources for clinical, sales, and reimbursement initiatives.
Negative Factors
Weak cash conversionNegative operating and free cash flow despite reported profitability indicate that earnings have not yet translated consistently into cash. Persistent cash conversion weakness could increase reliance on financing, limit investment flexibility, and make it harder to absorb execution or reimbursement delays.

AOTI, Inc. (AOTI) vs. iShares MSCI United Kingdom ETF (EWC)

-50%0%50%100%150%200%250%300%GB:AOTI+286.67%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 154.22M
Dividend Yield
―
Average Volume (3M)
149.34K
Price to Earnings (P/E)
76.2
Beta (1Y)
0.18
Revenue Growth
10.59%
EPS Growth
―
Country
UK
Employees
90
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

AOTI, Inc. Business Overview & Revenue Model

Company Description

AOTI, Inc. specializes in creating and marketing healthcare technologies specifically designed for treating persistent and hard-to-heal wounds. Among its offerings are the innovative Topical Wound Oxygen (TWO2) Therapy and the NEXA Negative Pressure...

How the Company Makes Money

AOTI makes money primarily by selling and/or renting its topical oxygen therapy systems and the associated single-use or recurring-use consumables required to operate those systems (e.g., wound dressings and related supplies used with the therapy). R...

AOTI, Inc. Earnings Call Summary

Earnings Call Date:Sep 30, 2026(Q2-2026)|% Change Since:11.54%|Next Earnings Date:May 03, 2027
Earnings Call SentimentPositive

The call was strongly optimistic, emphasizing 18.8% underlying growth, improved EBITDA margins, positive operating cash flow, clinical evidence, and the potential for CMS coverage to expand the addressable market by 65-fold. The main challenges were unpaid Arizona Medicaid receivables, slower Medicaid expansion, ongoing operational changes, and uncertainty over final Medicare reimbursement. Positive developments and stated opportunities significantly outweighed the disclosed challenges.

Positive Updates

Robust Underlying Revenue Growth
Underlying revenue growth was around 18.8%, excluding the Arizona Medicaid segment, while reported revenue growth was 10.8%, driven by the VA and Medicaid businesses.

Negative Updates

Arizona Medicaid Receivables and Patient Intake Halt
AOTI has been unable to collect billed revenue for Arizona Medicaid treatment due to issues including cyber breaches, Medicaid insurer turbulence, CTP fraud, and multiple Medicaid director changes. The company ceased taking on new Arizona Medicaid patients on April 1, 2026, and management said the timing of historical receivables recovery remains difficult to determine.

Company Guidance

For the rest of 2026, AOTI is expecting 2026 EBITDA to be in line with current consensus, which is $6.8 million as at 29th of September, and is confident with its net debt and cash outlook for the full year; it is expecting to continue its top-line growth in line with its guidance set at the time of its FY 2025 results, namely underlying mid-teens growth excluding Arizona Medicaid or low single-digit growth on a reported basis. The company expects to move towards the final LCD within the 365-day period, with the final LCD to complete by July 23rd of next year, and believes average patients per rep, currently around 20, could potentially double in the future, while its highest performing reps produce as much as five times as many as that.

AOTI, Inc. Financial Statement Overview

Summary

AOTI demonstrates strong top-line growth and a return to GAAP profitability. However, sharp gross margin contraction, increasing debt levels, and persistent negative cash flows highlight near-term liquidity and leverage risks.

Income Statement

75Positive

Balance Sheet

60Neutral

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue67.77M68.80M58.36M43.92M33.51M22.98M
Gross Profit36.40M37.01M51.35M37.59M2.86M45.36K
EBITDA7.79M7.95M2.64M-4.28M3.19M16.52K
Net Income2.64M2.76M-1.76M-8.19M-2.80M2.03M
Balance Sheet
Total Assets57.01M57.01M39.54M21.08M9.35M1.51M
Cash, Cash Equivalents and Short-Term Investments13.44M13.44M9.34M778.48K2.83M297.44K
Total Debt21.19M21.19M8.92M12.35M12.41M269.08K
Total Liabilities37.06M37.06M22.10M26.99M5.94M1.25M
Stockholders Equity19.94M19.94M17.44M-5.91M760.20K1.52M
Cash Flow
Free Cash Flow-6.74M-6.83M-7.85M-2.76M1.77M-428.43K
Operating Cash Flow-4.91M-4.96M-5.91M-1.45M2.77M-46.07K
Investing Cash Flow-1.83M-1.87M-1.94M-1.59M-3.13M-904.53K
Financing Cash Flow10.99M11.07M16.41M-202.81K5.72M-692.04K

AOTI, Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price145.00

Price Trends

50DMA132.98Positive
100DMA116.72Positive
200DMA82.22Positive

Market Momentum

MACD3.66Negative
RSI90.68Negative
STOCH75.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AOTI, the sentiment is Positive. The current price of 145.00 is above the 20-day moving average (MA) of 136.70, above the 50-day MA of 132.98, and above the 200-day MA of 82.22, indicating a bullish trend. The MACD of 3.66 indicates Negative momentum. The RSI at 90.68 is Negative, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AOTI.

AOTI, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:AOTI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:AOTIGB:AOTI70OutperformGBP 154.22M76.1712.91%―10.59%―
GB:EKFGB:EKF64NeutralGBP 102.28M41.383.58%―2.26%-57.04%
GB:DXRXGB:DXRX56NeutralGBP 161.28M-573.44-0.68%―20.14%82.22%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:ABDXGB:ABDX46NeutralGBP 21.48M-15.45-34.31%―30.42%43.16%
GB:RENXGB:RENX44NeutralGBP 35.87M-3.21675.00%―――
GB:VRCIGB:VRCI41NeutralGBP 12.33M-0.45-127.57%―77.87%84.36%

* Healthcare Sector Average

Performance Comparison

0%100%200%GB:AOTIGB:EKFGB:RENXGB:DXRXGB:VRCIGB:ABDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:AOTI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:AOTIAOTI, Inc.145.00107.50286.67%
GB:EKFEKF Diagnostics Holdings24.00-0.60-2.44%
GB:RENXRenalytix Plc OTC5.20-1.55-22.96%
GB:DXRXDiaceutics Plc183.5021.0012.92%
GB:VRCIVerici Dx Plc0.17-0.52-75.00%
GB:ABDXAbingdon Health PLC8.501.2517.24%

AOTI, Inc. Corporate Events

Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance

AOTI builds momentum ahead of transformative Medicare decision as H1 revenue and EBITDA climb

Positive
Sep 30, 2026

AOTI reported robust underlying performance for the first half of 2026, with revenue growth of 18.8 percent excluding Arizona Medicaid and EBITDA rising 16.6 percent to 3.6 million dollars, while operating cash flow turned positive and net debt edged...

Business Operations and StrategyRegulatory Filings and Compliance

AOTI Gains Unanimous Support in CMS Meeting on Medicare Coverage for Topical Oxygen Therapy

Positive
Aug 27, 2026

AOTI, Inc., a medical technology group specializing in topical oxygen therapy for chronic wounds and diabetic foot ulcers, delivers its patented TWO2 therapy as a non-invasive, home-based treatment designed to improve clinical outcomes and lower heal...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026